Home > Boards > US Listed > Medical - Equipment > Cytosorbents Corporation (CTSO)

Biotech, I have never seen a single post

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
fantomphan Member Profile
 
Followed By 8
Posts 1,482
Boards Moderated 0
Alias Born 12/15/13
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/18/2022 4:32:30 PM
CytoSorbents jumps 1.86% on prelim FY21 and Q4 revenue above the consensus Seeking Alpha - 1/18/2022 7:35:44 AM
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue PR Newswire (US) - 1/18/2022 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/7/2022 5:11:35 PM
Dawson James Remains a Buy on Cytosorbents (CTSO) TipRanks - 1/5/2022 4:10:04 AM
Dawson James Sticks to Their Buy Rating for Cytosorbents (CTSO) TipRanks - 1/5/2022 4:08:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/30/2021 5:29:04 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 12/30/2021 5:27:40 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/21/2021 9:01:13 AM
CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular PR Newswire (US) - 12/21/2021 7:05:00 AM
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb® in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO) PR Newswire (US) - 12/20/2021 7:10:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 12/13/2021 5:01:41 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 12/13/2021 9:06:01 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/26/2021 6:11:44 PM
CytoSorbents to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and Jefferies London Healthcare Conference PR Newswire (US) - 11/15/2021 4:30:00 PM
Cytosorbents EPS misses by $0.03, beats on revenue Seeking Alpha - 11/4/2021 4:29:11 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/4/2021 4:15:41 PM
CytoSorbents Reports Full Third Quarter 2021 Financial and Operational Results PR Newswire (US) - 11/4/2021 4:15:00 PM
Cytosorbents Q3 2021 Earnings Preview Seeking Alpha - 11/3/2021 5:35:41 PM
CytoSorbents Comments on REMOVE Study Presentation PR Newswire (US) - 10/20/2021 7:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/15/2021 6:26:17 AM
First Patient Enrolled in U.S. STAR-T Pivotal Trial Evaluating the DrugSorb-ATR™ Antithrombotic Removal System to Remove Ticagrelor During Cardiothoracic Surgery PR Newswire (US) - 10/14/2021 7:05:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/13/2021 7:01:40 AM
CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery PR Newswire (US) - 10/12/2021 4:38:00 PM
CytoSorbents Provides Preliminary Third Quarter Business Update and Revised 2021 Product Revenue Guidance PR Newswire (US) - 10/12/2021 4:35:00 PM
fantomphan   Monday, 10/18/21 10:14:45 AM
Re: biotech48 post# 26789
Post # of 27001 
Biotech, I have never seen a single post that would be considered positive or pro CTSO removed. Not a one. Critical ones? You betcha. So what's your beef? PS, as I've posted to you previously, you and I are on the same team and want this to work out badly. I'm sure you view me negatively, at least my posts, but I'm sorry, when I see something that walks like a duck.....

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences